U.S. markets closed

OptiNose, Inc. (OPTN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6200-0.0800 (-2.16%)
At close: 4:00PM EDT

OptiNose, Inc.

1020 Stony Hill Road
Suite 300
Yardley, PA 19067
United States
267 364 3500
http://www.optinose.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees204

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter K. MillerCEO & Director999.81kN/A1961
Dr. Ramy A. Mahmoud M.D., M.P.H.Pres & COO737.55kN/A1965
Mr. Keith Alan GoldanChief Financial Officer600.21kN/A1971
Mr. Michael F. MarinoChief Legal Officer & Corp. Sec.604.71kN/A1976
Mr. Victor M. ClavelliChief Commercial Officer584.2kN/A1973
Mr. Jonathan NeelyVP of Investor Relations & Bus. OperationsN/AN/AN/A
Ms. Karen E. BrophyVP of HRN/AN/A1963
Mr. John MessinaSr. VP of Clinical Devel. & Medical AffairsN/AN/AN/A
Ms. Helena Kyttari DjupeslandCo-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Corporate Governance

OptiNose, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.